Access Program for Unapproved and Off‐Label Drug Use in Pediatric BRAF V600E‐Mutated Brain Tumors in Japan
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.31510 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Maya Suzuki und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics. Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Off-Label Use, Brain Neoplasms, Glioma. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Programs allowing access to investigational drugs and off‐label drug use for serious diseases have often been applied to pediatric cancers. A clinical study conducted under the Japanese “Patient‐Proposed Healthcare Services” evaluated the efficacy and safety of dabrafenib plus trametinib in children with BRAF V600 mutant glioma (jRCTs071210071). This study successfully provided unapproved and off‐label medications to four enrolled patients, two with low‐grade glioma and two with high‐grade glioma (median age: 10.5 years), until regulatory approval. The timeframe and data collection from such access programs need to be optimized for pediatric patients in accordance with the healthcare system of each nation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics. Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan.
- Department of Pediatrics, National Hospital Organization (NHO) Kyushu Cancer Center, Fukuoka, Japan.
- Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
ORCID-Profile: Maya Suzuki, Tamaki Ueda, Shunsuke Yamamoto, Hironori Goto
Zitieren
APA
Suzuki, M., Koga, Y., Kawasaki, T., Ueda, T., Yamamoto, S., Goto, H., Kishimoto, J., Ishida, E., Todaka, K., Sonoda, K. H., Oda, Y., Koji, Y., Sakai, Y., & Ohga, S. (2025). Access Program for Unapproved and Off‐Label Drug Use in Pediatric BRAF V600E‐Mutated Brain Tumors in Japan. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31510
Vancouver
Suzuki M, Koga Y, Kawasaki T, Ueda T, Yamamoto S, Goto H, et al. Access Program for Unapproved and Off‐Label Drug Use in Pediatric BRAF V600E‐Mutated Brain Tumors in Japan. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31510
BibTeX
@article{Suzuki2025,
author = {Suzuki, Maya and Koga, Yuhki and Kawasaki, Terumi and Ueda, Tamaki and Yamamoto, Shunsuke and Goto, Hironori and Kishimoto, Junji and Ishida, Eiko and Todaka, Koji and Sonoda, Koh-Hei and Oda, Yoshinao and Koji, Yoshimoto and Sakai, Yasunari and Ohga, Shouichi},
title = {Access Program for Unapproved and Off‐Label Drug Use in Pediatric BRAF V600E‐Mutated Brain Tumors in Japan},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.31510}
}
EUVIMED